Iopamidol: new, nonionic contrast agent for excretory urography

Area of Science:

• Radiology
• Pharmacology
• Nephrology

Background:

• Excretory urography is a key diagnostic tool.
• Ionic contrast agents, while effective, can have adverse effects.
• There is a need for safer, effective contrast media.

Purpose of the Study:

• To evaluate the safety and efficacy of iopamidol, a nonionic contrast agent.
• To compare iopamidol with traditional ionic contrast agents.
• To determine optimal dosing for excretory urography.

Main Methods:

• 18 patients underwent excretory urography with iopamidol.
• Safety was assessed via clinical observation and laboratory tests (serum chemistries, CBC, urinalysis, ECG).
• Diagnostic quality of urograms was evaluated, and iopamidol was compared head-to-head with meglumine diatrizoate in a blinded study.

Main Results:

• No adverse events or side effects were reported in any of the 18 patients.
• Laboratory tests and ECGs remained normal.
• Urograms were of good or excellent quality at doses of 200-250 mg I/kg, with comparable quality to meglumine diatrizoate at a lower iodine dose (17.4 g vs 29 g).
• Lower doses (120 mg I/kg) resulted in poor urogram quality.

Conclusions:

• Iopamidol is a safe and effective nonionic contrast agent for excretory urography.
• It provides diagnostic quality comparable to ionic agents but with a lower iodine load.
• Iopamidol may offer a safer alternative to current ionic contrast media.